[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lung-transplant-rejection\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lung-transplant-rejection":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,41,68,93,120,147,171,195,219],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100522393","phase-3-a-study-to-test-how-effective-belumosudil-tablets-are-for-treating-adult-participants-with-chronic-lung-allograft-dysfunction-100522393",false,"NCT06082037","A Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants With Chronic Lung Allograft Dysfunction","A Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 3 Study, Followed by Open-label Extensions, to Evaluate the Efficacy of Oral Belumosudil in Adult Participants With Chronic Lung Allograft Dysfunction (CLAD) Following Bilateral Lung Transplantation","ROCKaspire","Inclusion Criteria:\n\n* Participant ≥1 year post bilateral lung transplantation at the time of screening\n* Participants presenting with CLAD Stage 1 or 2: FEV1 from \\>50% to 80% of post-transplant baseline at screening and at randomization\n* Participants who have received at least 8 weeks of azithromycin (≥250 mg\u002Fday, at least 3 times a week) prior to randomization\n\nExclusion Criteria:\n\n* FEV1 ≤50% of the post-transplant baseline value (CLAD 3 and 4)\n* Lung function decline that can be explained by non-CLAD causes including but not limited to acute lung allograft rejection (\\>A1), antibody-mediated rejection, airway stenosis, or tracheobronchomalacia\n\nThe above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.","ALL","18 Years",{"count":20,"type":21},180,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","This double-blind, randomized, placebo-controlled, multinational, multicenter, parallel-group, Phase 3, 2-arm, study will investigate the efficacy and safety of belumosudil compared with placebo, both administered on top of azithromycin and standard-of-care regimen of immunosuppression in male or female participants at least 1 year after bilateral lung transplant, who are at least 18 years of age and who have evidence of progressive CLAD despite azithromycin therapy.\n\nStudy details include:\n\nThe study duration will be up to 31 weeks for participants not entering the open-label extension (OLE) period and up to 57 weeks for participants entering the OLE period but not the long-term OLE.\n\nThe treatment duration will be up to 26 weeks for participants not entering the OLE period and up to 52 weeks for participants entering the OLE period but not the long-term OLE.\n\nThe number of visits will be up to 10 visits for participants not entering the OLE period and up to 16 visits for participants entering the OLE period but not the long-term OLE.\n\nFor participants who enter the long-term OLE, treatment and study participation will continue with visits every 12 weeks per protocol specifications.",[27],"Lung Transplant Rejection","RECRUITING","2026-06-25",{"date":31,"type":32},"2026-06-29","ACTUAL",{"date":34,"type":32},"2023-10-10",{"date":36,"type":21},"2030-10-01",{"name":38,"class":39},"Sanofi","INDUSTRY",79,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":52,"conditions":53,"keywords":54,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":67},"100271379","diagnostic-and-therapeutic-applications-of-microarrays-in-lung-transplantation-100271379","NCT02812290","Diagnostic and Therapeutic Applications of Microarrays in Lung Transplantation","Multi-Centric Observational Study to Analyze the Diagnostic Molecular Features in the Clinical Setting of Lung Allograft Biopsies","INTERLUNG","Inclusion Criteria:\n\n* All lung transplant recipients undergoing a biopsy as determined by their surgeon or physician.\n\nExclusion Criteria:\n\n* Patients who declined participation or unable to give informed consent.",{"count":50,"type":21},700,"OBSERVATIONAL","Objective: To evaluate the potential impact of molecular phenotyping of transbronchial biopsies in lung transplant recipients with allograft dysfunction, and the potential for developing a safer endobronchial mucosal biopsy format.",[27],[55,56],"antibody mediated rejection","T cell mediated rejection","2026-05-25",{"date":59,"type":32},"2026-05-28",{"date":61,"type":4},"2016-05",{"date":63,"type":21},"2027-12",{"name":65,"class":66},"University of Alberta","OTHER",11,{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":74,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":76,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":78,"conditions":79,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":92},"100546773","prospective-multicenter-research-on-donor-and-recipient-management-strategies-to-improve-lung-transplant-outcomes-100546773","NCT06399302","Prospective Multicenter Research on Donor and Recipient Management Strategies to Improve Lung Transplant Outcomes","Prospective Multicenter Research on Donor and Recipient Management Strategies to Improve Lung Transplant Outcomes: PROMISE-Lung Study","PROMISE","Inclusion Criteria:\n\n1. Able to understand and provide informed consent\n2. ≥ 18 years of age at the time of written informed consent\n3. Anticipated listing or listed for a single or bilateral cadaveric donor lung transplant or having received a lung transplant within 30 days\n\n   * Participants undergoing repeat lung transplantation or multi-organ transplantation are eligible if they meet the inclusion\u002Fexclusion criteria.\n\nExclusion Criteria:\n\n1. Unwillingness of a participant or legally authorized representative (LAR) to give written informed consent or comply with study protocol\n2. Pregnancy or plans to become pregnant\n3. Past or current medical problems or findings from physical examination or laboratory testing, which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements or that may impact the quality or interpretation of the data obtained from the study.",{"count":77,"type":21},2600,"This project aims to collect detailed clinical data, blood samples, and patient-reported outcomes from 2,600 lung transplant candidates, donors, and recipients at Lung Transplant Centers. The goal is to create a robust resource for various research objectives, including studying the impact of variations in donor and medical practices on clinical outcomes. The project also seeks to identify serum biomarkers associated with or predictive of specific post-transplant complications and conditions.",[80,81,27,82],"Lung Transplant; Complications","Lung Transplant; Infection or Inflammation","Lung Transplant Failure","2026-05-07",{"date":85,"type":32},"2026-05-11",{"date":87,"type":32},"2024-09-03",{"date":89,"type":21},"2027-06-30",{"name":91,"class":66},"Duke University",19,{"id":94,"slug":95,"hasResults":11,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":4,"eligibilityCriteria":99,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":100,"enrollmentInfo":101,"targetDuration":4,"studyType":22,"phases":103,"briefSummary":105,"conditions":106,"keywords":107,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":119},"100579446","cryoprobe-biopsy-and-chronic-rejection-in-lung-transplant-recipients-100579446","NCT06824402","Cryoprobe Biopsy and Chronic Rejection in Lung Transplant Recipients","A Prospective, Randomized Clinical Trial to Evaluate the Feasibility of Miniature Cryoprobe Biopsy to Detect Acute and Chronic Lung Transplant Rejection in Lung Transplant Recipients","Inclusion Criteria\n\n* Male and female lung transplant recipients age \\>18 at the time of informed consent\n* Patients clinically meet indication for post-transplant lung biopsy or planned routine surveillance and have been scheduled for bronchoscopy with transbronchial biopsy.\n* Be willing and able to sign the informed consent.\n\nExclusion Criteria\n\n* Patients with known bleeding diathesis\n* Platelet count \\<50,000 per μL within 14 days of the biopsy procedure\n* Current use of systemic anticoagulation or antiplatelet therapy without the ability to hold therapy for the recommended amount of time prior to an invasive procedure (aspirin monotherapy is acceptable)\n* Inability or unwillingness to give informed consent or study procedures\n* Pregnant or nursing females, or females who intend to become pregnant\n* Females of child-bearing potential who decline a pregnancy test prior to enrollment\n* If an investigator does not feel that this study is in the subject's best interest or would be a good fit for the study.\n* International Normalized Ratio (INR) \\>1.5\n* Do Not Resuscitate (DNR) status\n* Do Not Intubate (DNI) status\n* Single lung transplant recipients","99 Years",{"count":102,"type":21},100,[104],"NA","The goal of this clinical trial is to evaluate which biopsy collection method helps to better diagnose rejection and relevant pathologic findings in lung transplant recipients. The main questions it aims to answer are:\n\nDoes the 1.1 mm cryoprobe or the biopsy forceps provide better quality samples of lung tissue for detecting rejection in transplant recipients?\n\nHow much tissue is adequate for lung transplant 1.1 mm cryobiopsy samples as compared to biopsy forceps?\n\nWhich samples received by the pathologist did they find they were most confident to exclude rejection, based on their satisfaction with the samples?\n\nWhich collection method has the least amount of procedural time?\n\nResearchers will compare lung tissue samples obtained using a 1.1mm cryoprobe and a biopsy forceps during the lung transplant.\n\nParticipants will:\n\nBe randomly assigned to receive either the cryoprobe or biopsy forceps collection method at the time of biopsy.\n\nAssessed for any adverse events following the biopsy for up to 30 days after transplant.",[27],[108,109],"Lung Transplant","Bronchoscopy","2026-04-27",{"date":112,"type":32},"2026-05-01",{"date":114,"type":32},"2025-02-17",{"date":116,"type":21},"2027-09-30",{"name":118,"class":66},"Mayo Clinic",1,{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":4,"eligibilityCriteria":126,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":127,"enrollmentInfo":128,"targetDuration":4,"studyType":22,"phases":130,"briefSummary":132,"conditions":133,"keywords":134,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":119},"100596549","phase-2-developing-hyperpolarized-gas-mri-signatures-to-detect-and-manage-acute-cellular-rejection-100596549","NCT07046910","Developing Hyperpolarized Gas MRI Signatures to Detect and Manage Acute Cellular Rejection","Advanced Immunoclinical Phenotyping of Rejection in Lung Transplant","Inclusion Criteria:\n\n* All subjects must be willing to participate and undergo the procedure, and be managed as outpatients\n* HXe MRI-specific Inclusion\n* All patients who successfully underwent a lung transplant at the University of Virginia\n* Followed by the medical lung transplant team for the post-lung transplant rejection surveillance program at the University of Virginia\n* a clinical diagnosis of lung transplant within the past 12 months\n* absence of any significant allograft dysfunction\u002Frejection at the time of the 12-month surveillance bronchoscopy\n* the ability to understand a written informed consent form and comply with the requirements of the study.\n* have an acceptable pre-bronchoscopy pulmonary function test: FEV1\\>45% before use of any bronchodilator\n* Must have acceptable pre-procedural screening studies.\n* Complete Blood Count: normal WBC, Hgb, and PLT\n* PT: Normal \\\u003C 1.2\n* Basic Metabolic Panel: Normal\n\n  1. Scenario 1 (two visits): Standard bronchoscopy with Normal MRI results and without a diagnosis of acute rejection after bronchoscopy.\n  2. Scenario 2 (two visits): Navigational bronchoscopy with abnormal MRI result but without a diagnosis of acute rejection after bronchoscopy by clinical pathology.\n  3. Scenario 3 (three or four visits): Navigational bronchoscopy with abnormal MRI result and a diagnosis of acute rejection after bronchoscopy by clinical pathology at the first visit, the second visit, or both visits.\n  4. Scenario 4 (one visit): Subjects who previously signed Part 2 Substudy corresponding to the First HXe MRI visit of the Part 3 Substudy (6 or 12 month evaluation). They will be asked to join the Part 3 Substudy to undergo a 24-month follow-up evaluation, including MRI and bronchoscopy, as described for Scenarios 1, 2, or 3.\n\n     Exclusion Criteria:\n\n  \u003C!-- -->\n\n  1. Unable to Consent\n  2. Continuous oxygen use at home.\n  3. Blood oxygen saturation of less than 92% as measured by pulse oximetry on the day of imaging.\n  4. FEV1 percent predicted less than 25%.\n  5. Pregnancy or lactation.\n  6. Claustrophobia, inner ear implants, aneurysms or other surgical clips, metal foreign bodies in the eye, pacemakers, or other contraindications to MR scanning. Subjects with any implanted device that cannot be verified as MRI compliant will be excluded.\n  7. Chest circumference greater than that of the xenon MR and\u002For helium coil. The circumference of the coil is approximately 42 inches.\n  8. History of congenital cardiac disease, chronic renal failure, or cirrhosis.\n  9. Inability to understand simple instructions or to hold still for approximately 10 seconds.\n  10. History of respiratory infection within 2 weeks prior to the MR scan\n  11. History of MI, stroke, and\u002For poorly controlled hypertension.\n  12. Failure to complete study-related procedures\n  13. Unavailability of a reliable communication network and contacts for follow-up with the second in-house backup contact\n  14. Patient actively smokes.\n  15. Before 48 hours, any event being considered to be too risky to preclude surveillance bronchoscopy: SaO2 \\\u003C90%, \\>16 puffs\u002F24 hours of short-acting β-agonist (SABA), worsening symptoms prompting the use of any inhalers, FEV1 \\\u003C 45% before using a bronchodilator.\n  16. acute or chronic renal failure\n  17. uncontrolled coronary artery disease or congestive heart failure; uncontrolled diabetes mellitus; uncontrolled hypertension, liver disease; history of neurologic diseases, including stroke, any disease concerning fibrotic processes.\n  18. Pregnant females will be excluded\n  19. Claustrophobic or too large to fit into the available MR chest RF coils.\n\n      \\-","80 Years",{"count":129,"type":21},60,[131],"PHASE2","Lung transplantation (LT) is the only definitive therapy for many patients with end-stage lung diseases. The supply of donors' lungs is the biggest bottleneck to performing a lung transplant, and many patients die while waiting. Acute Cellular Rejection (ACR) is a significant risk factor for developing chronic allograft failure, a primary reason for death in this patient population. These observations highlight the importance of early diagnosis and management of ACR to prevent chronic graft failure. The preliminary results support the idea that Hyperpolarized Gas Magnetic Resonance Imaging has excellent potential to address this clinical gap. This study hypothesizes that optimized hyperpolarized gas magnetic resonance imaging (HGMRI) signatures can detect early pathophysiologic derangements in lung allografts consistent with ACR. This study also hypothesizes that the optimized HGMRI signatures will correlate with single-cell transcriptomic signatures that reflect dysregulated immune responses associated with ACR.",[27],[135,136,137],"lung transplant","hyperpolarized xenon-129 MRI","bronchoscopy","2026-03-14",{"date":140,"type":32},"2026-03-17",{"date":142,"type":32},"2019-04-01",{"date":144,"type":21},"2029-03-31",{"name":146,"class":66},"University of Virginia",{"id":148,"slug":149,"hasResults":11,"nctId":150,"briefTitle":151,"officialTitle":152,"acronym":153,"eligibilityCriteria":154,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":155,"targetDuration":4,"studyType":22,"phases":157,"briefSummary":159,"conditions":160,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":163,"startDateStruct":165,"completionDateStruct":167,"leadSponsor":169,"locationsCount":119},"100555614","phase-1-safety-of-endobronchial-mesenchymal-stromal-cells-in-the-treatment-of-chronic-lung-allograft-dysfunction-100555614","NCT06514378","Safety of Endobronchial Mesenchymal Stromal Cells in the Treatment of Chronic Lung Allograft Dysfunction","An Open Label, Randomised, Controlled Clinical Trial to Asses the Safety of Endobronchial Administration of Allogneic Mesenchymal Stromal Cells in Patients With Lung Trasplant Chronic Rejection: Endosclad Study.","ENDOSCLAD","Inclusion Criteria:\n\nPatients should have signed written informed consent. Adult patients ≥18 years of age at the time of enrolment Patients recipients of a uni or bipulmonary transplant An established diagnosis of BOS ≧ 0p (FEV1≤90% and \u002F or FEF 25-75% ≤ of the baseline value with no other justifying cause) in the last 6 months.\n\nExclusion Criteria:\n\n* History of lobar transplantation History of heart-lung transplantation Active infection at the time of inclusion. Active Acute Rejection not treated at the time of inclusion. Oncological history (except cutaneous basal cell or carcinoma in situ) Systemic autoimmune diseases. Active HIV \u002F HBV \u002F HCV infection (confirmed by serology or PCR) Proximal airway stenosis Pregnancy Performance status 3 or 4 (confined to bed or chair for more than 50% of waking hours, able only to perform some self-care activities) Estimated survival less than 3 months. Known hypersensitivity to components used in the production of allogeneic MSCs. Any circumstance that, in the opinion of the investigator, compromises the patient's ability to participate in the clinical trial.",{"count":156,"type":21},12,[158],"PHASE1","Lung transplantation is the only therapeutic alternative for more and more patients with respiratory diseases in their most advanced stages.\n\nThe most limiting factor to achieve long term survival si chronic lung allograft dysfunction, a multifactorial disease without an effective treatment.\n\nThe immunomodulatory capacity of mesenchymal stem cells enables them to be a potential therapeutic agent for this condition.\n\nThe objective of this study is to assess the safety of endobronchial administration of allogeneic MSCs in patients with chroniclung allograft dysfunction.",[161,27],"Chronic Lung Disease","2024-07-25",{"date":164,"type":32},"2024-07-26",{"date":166,"type":32},"2023-09-19",{"date":168,"type":21},"2026-03-31",{"name":170,"class":66},"Instituto De Investigación Sanitaria Puerta De Hierro-Segovia De Arana",{"id":172,"slug":173,"hasResults":11,"nctId":174,"briefTitle":175,"officialTitle":176,"acronym":177,"eligibilityCriteria":178,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":179,"targetDuration":4,"studyType":22,"phases":181,"briefSummary":182,"conditions":183,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":186,"startDateStruct":188,"completionDateStruct":190,"leadSponsor":192,"locationsCount":194},"100524762","a-prospective-randomized-trial-of-ecp-in-subclinical-amr-100524762","NCT06112951","A Prospective Randomized Trial of ECP in Subclinical AMR","The Use of Extracorporeal Photopheresis as Immunomodulatory Therapy of Subclinical Antibody-mediated Rejection After Lung Transplantation: a Prospective RCT","EUROEXPORT-DSA","Inclusion Criteria:\n\n* Bilateral lung transplantation\n* dnDSAs \\> 3 months with a MFI \\> 1000\n* No signs of allograft dysfunction\n* Alemtuzumab induction therapy\n\nExclusion Criteria:\n\n* Inclusion in other studies\n* Retransplantation\n* Multi-organ transplantation\n* \\> 12 months after transplantation",{"count":180,"type":21},80,[104],"The goal of this clinical trial is to evaluate the therapeutic effect of extracorporeal photopheresis in subclinical antibody-mediated rejection after lung transplantation.The main questions it aims to answer are:\n\n1. Does ECP therapy result in a significant reduction in MFI (Mean Fluorescence Intensity) from the baseline MFI in clinically stable patients with persistent (\\>6 months) dnDSAs (MFI\\>1000)?\n2. What is the impact of ECP therapy on the following outcomes in these patients: ACR, clinical AMR, CLAD, infections, drop-out rate, survival, adverse events?\n\nParticipants will be randomized into two groups. Each group will include 40 patients. The control group will be observed and no active treatment will be administered. The treatment group will receive extracorporeal photopheresis. First, a two-day treatment cycle will be performed once every second week for the first two months. Then, a two-day treatment cycle will be performed once a month for 6 months.\n\nResearchers will compare the two groups regarding: MFI value, development of ACR, clinical AMR, CLAD, infections, survival, adverse events, immunophenotyping, miRNA expression profiling, cytokine expression, gene expression signature of PBMCs and proteomic characterization.",[184,27],"Antibody-mediated Rejection","2024-07-08",{"date":187,"type":32},"2024-07-09",{"date":189,"type":32},"2024-03-01",{"date":191,"type":21},"2027-06-01",{"name":193,"class":66},"Medical University of Vienna",7,{"id":196,"slug":197,"hasResults":11,"nctId":198,"briefTitle":199,"officialTitle":199,"acronym":200,"eligibilityCriteria":201,"healthyVolunteers":11,"sex":17,"minAge":202,"maxAge":4,"enrollmentInfo":203,"targetDuration":4,"studyType":22,"phases":205,"briefSummary":206,"conditions":207,"keywords":209,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":210,"lastUpdatePostDateStruct":211,"startDateStruct":213,"completionDateStruct":215,"leadSponsor":217,"locationsCount":119},"100426771","diagnostic-and-prognostic-biomarkers-of-transplant-dysfunction-in-the-context-of-lung-transplantation-100426771","NCT04837339","Diagnostic and Prognostic Biomarkers of Transplant Dysfunction in the Context of Lung Transplantation","DATACOL","Inclusion Criteria:\n\n* Men or women over 15 years of age\n* Suffering from a lung condition requiring a transplant planned at Foch Hospital or being followed up at Foch Hospital following a lung transplant\n* Have signed the informed consent form and for patients aged 15 to 18 years that the person(s) exercising parental authority has\u002Fhave signed the informed consent.\n* Be affiliated with a Health Insurance plan.\n\nExclusion Criteria:\n\n* Pregnant, parturient and\u002For lactating woman\n* Hemoglobin level less than or equal to 8g\u002Fdl\n* Persons of full age who are subject to a legal protection measure or who are unable to express their consent\n* Persons under the protection of justice\n* Not being able to follow the study requirements for geographical, social or psychological reasons\n* Patient refusal.","15 Years",{"count":204,"type":21},900,[104],"Transplant results vary considerably from one organ to another. Lung transplantation has poorer long-term outcomes than other solid organ transplants, with a current median post-transplant survival of 6.0 years. Allograft rejection remains the leading cause of morbidity and mortality in all organ groups and is the leading cause of death, accounting for more than 40% of deaths beyond the first year after lung transplantation.\n\nEach dysfunctions impacts the fate of the graft and therefore the survival of the recipient. Their early and precise diagnosis is therefore a major issue. The identification of the pathophysiological mechanisms underlying these different subtypes of dysfunction (transcriptomics, polymorphism of target genes of the immune system or tissue repair, cell phenotyping) is an essential step. It can only be done on the basis of a collection of samples linked to a clinical database allowing to contextualize each sample.",[27,82,80,208],"Lung Transplant Failure and Rejection",[200],"2022-08-02",{"date":212,"type":32},"2022-08-03",{"date":214,"type":32},"2022-03-17",{"date":216,"type":21},"2037-03",{"name":218,"class":66},"Hopital Foch",{"id":220,"slug":221,"hasResults":11,"nctId":222,"briefTitle":223,"officialTitle":224,"acronym":4,"eligibilityCriteria":225,"healthyVolunteers":11,"sex":17,"minAge":226,"maxAge":227,"enrollmentInfo":228,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":230,"conditions":231,"keywords":234,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":239,"lastUpdatePostDateStruct":240,"startDateStruct":242,"completionDateStruct":244,"leadSponsor":246,"locationsCount":119},"100468082","exhaled-breath-particles-in-lung-transplantation-100468082","NCT05375149","Exhaled Breath Particles in Lung Transplantation","Exhaled Breath Particles as a Clinical Indicator for Acute and Chronic Rejection After Lung Transplantation","Inclusion Criteria:\n\n* Patients who have undergone LTx at Skåne University Hospital, SUS Lund\n\nExclusion Criteria:\n\n* None","16 Years","75 Years",{"count":229,"type":21},150,"Lung transplantation (LTx) is the only effective treatment for patients with end stage lung disease. Of the major organs transplanted, survival following LTx is the lowest with a mean of 5 years. Despite improvements, primary graft dysfunction (PGD) remains the leading cause of early mortality and contributes to the development of chronic lung allograft dysfunction (CLAD) that remains the leading cause of late mortality. Earlier detection of rejection after LTx is of substantial importance as it would improve the possibilities of treatment and could increase survival.\n\nThe investigators have shown in previous work that exhaled breath particles (EBP) reflect the composition of respiratory tract lining fluid (RTLF). EBP and particle flow rate (PFR) can be used as non-invasive methods for early detection and monitoring of airway diseases such as acute respiratory distress syndrome (ARDS). It has also been shown that the particle flow prolife after lung transplantation differs between patients who develop PGD and those who do not and that the composition of EBP differs between patients with and without bronchiolitis obliterans syndrome (BOS), an obstructive form of CLAD.\n\nSamples of EBP and measurements of PFR will be collected from lung transplanted patients. Membranes with EBP will be saved for molecular analysis. The investigators aim to identify potential particle flow patterns and biomarkers for earlier detection of rejection after lung transplantation.",[27,232,233],"Primary Graft Dysfunction","Chronic Rejection of Lung Transplant",[235,236,237,232,238],"Exhaled Breath Particles","PExA","Lung transplantation","Chronic Lug Allograft Dysfunction","2022-05-10",{"date":241,"type":32},"2022-05-16",{"date":243,"type":32},"2018-09-18",{"date":245,"type":21},"2026-09",{"name":247,"class":66},"Lund University Hospital"]